Merck/Schering Vytorin Launch Could Be Aided By New Cholesterol Guidelines
Revised cholesterol treatment guidelines could result in increased use of combination lipid-lowering therapies as Merck/Schering-Plough's Vytorin enters the market
You may also be interested in...
Clinicians recently took to the pages of the Journal of the American Medical Association to argue the appropriateness of using statin therapy as primary prevention in patients who are not already at high risk for a cardiovascular event. Such scrutiny comes as NIH prepares to issue new treatment guidelines to a market newly saturated with popular generic options, and as pharmaceutical companies assess how best to approach the dyslipidemia field.
An additional 1.4 million patients in England and Wales are expected to begin using statins as a result of guidance directing doctors to identify patients at high-risk for cardiovascular disease